Carlyle Leads USD123m Series D for Chinese Biotech Abbisko

The Carlyle Group led a USD123m Series D for China-based biotech firm Abbisko, with participation from Warburg Pincus, OrbiMed, and Lake Bleu Capital. Janchor Partners, Sage Partners, SHC, and Greater Bay Area Homeland Development Fund also participated in the round, and existing investors Lilly Asia Ventures, Temasek Holdings,… Read More

Sequoia China Leads USD150m Series B for Chinese Biotech Visen Pharmaceuticals

Sequoia Capital China led a USD150m Series B for China-based biotech firm Visen Pharmaceuticals, with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, as well as follow-on from existing investors, including Ascendis Pharma A/S, Vivo Capital, and… Read More

IDB Commits Combined USD30m to Vinci and HMC Funds

IDB Invest has agreed to commit a combined USD30m to funds managed by Vinci Partners and HMC Capital. IDB agreed to invest up to USD10m in Vinci Impact and Return Fund IV, a fund targeting investments in SMEs across the education, health care, IT, and environmentally friendly consumer… Read More

OP Finnfund Global Impact Fund I Reaches USD166m Second Close

OP Finnfund Global Impact Fund I has reached a EUR135m (approximately USD166m) second close. The impact vehicle, which targets investments in emerging markets across renewable energy, financial institutions, and sustainable agriculture, reached a EUR76m (~USD93.5m) first close in June 2020. The second round of funding ended in December… Read More



(default archive template)